Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD])

被引：0
|
作者：
Tabernero, J.
Aranda, E.
Gomez, A.
Massuti, B.
Sastre, J.
Abad, A.
Valladares, M.
Rivera, F.
Safont, M.
Diaz-Rubio, E.
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Hosp Reina Sofia, Cordoba, Spain
[3] Hosp Gen Alicante, Alicante, Spain
[4] Hosp Clin San Carlos, Madrid, Spain
[5] Univ Hosp Germans Trias & Pujol ICO, Barcelona, Spain
[6] Complejo Hosp Univ La Coruna, La Coruna, Spain
[7] Hosp Marques de Valdecilla, Cantabria, Spain
[8] Hosp Gen Valencia, Valencia, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3501
引用
收藏
页数：1
相关论文
共 50 条
  • [21] XELOX plus bev plus tislelizumab for first-line treatment of MSS/pMMR RAS-mutated mCRC: A single-arm, phase II study
    Ou, K.
    Ma, X.
    Cao, B.
    Yang, W.
    Yang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S439 - S440
  • [22] SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6+selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC).
    Gibbs, Peter
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Gebski, Val
    Van Buskirk, Mark
    Van Hazel, Guy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev plus selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC).
    Gibbs, Peter
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Peeters, Marc
    Perez, David
    Robinson, Bridget Anne
    Strickland, Andrew
    Ferguson, Tom
    Rodriguez, Javier
    Kroening, Hendrik
    Wolf, Ido
    Ganju, Vinod
    Walpole, Euan Thomas
    Boucher, Eveline
    Tichler, Thomas E.
    Gebski, Val
    Van Buskirk, Mark
    Van Hazel, Guy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [24] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Clemens Giessen
    Ludwig Fischer von Weikersthal
    Axel Hinke
    Sebastian Stintzing
    Frank Kullmann
    Ursula Vehling-Kaiser
    Julia Mayerle
    Markus Bangerter
    Claudio Denzlinger
    Markus Sieber
    Christian Teschendorf
    Jens Freiberg-Richter
    Christoph Schulz
    Dominik Paul Modest
    Nicolas Moosmann
    Philipp Aubele
    Volker Heinemann
    BMC Cancer, 11
  • [25] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Giessen, Clemens
    von Weikersthal, Ludwig Fischer
    Hinke, Axel
    Stintzing, Sebastian
    Kullmann, Frank
    Vehling-Kaiser, Ursula
    Mayerle, Julia
    Bangerter, Markus
    Denzlinger, Claudio
    Sieber, Markus
    Teschendorf, Christian
    Freiberg-Richter, Jens
    Schulz, Christoph
    Modest, Dominik Paul
    Moosmann, Nicolas
    Aubele, Philipp
    Heinemann, Volker
    BMC CANCER, 2011, 11
  • [26] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Li, Yu Hong
    Luo, Hui Yan
    Wang, Feng Hua
    Wang, Zhi Qiang
    Qiu, Miao Zhen
    Shi, Yan Xia
    Xiang, Xiao Juan
    Chen, Xiao Qing
    He, You Jian
    Xu, Rui Hua
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (04) : 503 - 510
  • [27] Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).
    Arnold, Dirk
    Andre, Thierry
    Bennouna, Jaafar
    Sastre, Javier
    Osterlund, Pia J.
    Greil, Richard
    Van Cutsem, Eric
    Von Moos, Roger
    Reyes-Rivera, Irmarie
    Bendahmane, Belguendouz
    Kubicka, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Yu Hong Li
    Hui Yan Luo
    Feng Hua Wang
    Zhi Qiang Wang
    Miao Zhen Qiu
    Yan Xia Shi
    Xiao Juan Xiang
    Xiao Qing Chen
    You Jian He
    Rui Hua Xu
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 503 - 510
  • [29] Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) plus bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966
    Cassidy, J.
    Cunningham, D.
    Berry, S. R.
    Rivera, F.
    Clarke, S. J.
    Kretzschmar, A.
    Diaz-Rubio, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): german AIO KRK0110 (ML22011) - study
    Modest, D. P.
    von Weikersthal, Fischer L.
    Decker, T.
    Vehling-Kaiser, U.
    Uhlig, J.
    Schenk, M.
    Freiberg-Richter, J.
    Peuser, B.
    Denzlinger, C.
    Reddemann, Peveling Genannt C.
    Graeven, U.
    Schuch, G.
    Schwaner, I.
    Stahler, A.
    Jung, A.
    Held, S.
    Stintzing, S.
    Giessen-Jung, C.
    Heinemann, V.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 123 - 123
12345